Stock Code: 300149 Stock Abbreviation: ChemPartner PharmaTech
ChemPartner PharmaTech Co., Ltd.
(ChemPartner PharmaTech Co., Ltd.)
(No. 164, Shengli South Road, Jianghai District, Jiangmen City, Guangdong Province)
2024 Annual Prospectus for Issuance of Shares to Specific Targets
(Draft)
Sponsor (Lead Underwriter)
CITIC Securities Company Limited
North Tower, Excellence Times Plaza (Phase II), No. 8 Central Third Road, Futian District, Shenzhen, Guangdong Province
June 2026
Statement
The Company and all directors and senior management guarantee that the contents of this prospectus are true, accurate, and complete, free from false records, misleading statements, or major omissions, and undertake corresponding legal liabilities in accordance with the principle of good faith.
The person in charge of the Company, the person in charge of accounting work, and the person in charge of the accounting institution guarantee the truthfulness and completeness of the financial and accounting data in this prospectus.
Any decision or opinion made by the CSRC or the exchange regarding this issuance does not indicate their guarantee of the truthfulness, accuracy, or completeness of the application documents and disclosed information, nor does it constitute a substantive judgment or guarantee of the issuer's profitability, investment value, or investor returns. Any statement to the contrary is a false representation.
In accordance with the Securities Law, after the securities are issued according to law, the issuer is responsible for changes in its operations and earnings. Investors shall independently judge the investment value of the issuer, make their own investment decisions, and bear the investment risks arising from changes in the issuer's operations and earnings or fluctuations in securities prices after the issuance.
Important Matters Notice
The Company specifically reminds investors to read the full text of this prospectus carefully before making investment decisions and to pay special attention to the following important matters.
I. Overview of the Issuance
(I) Type and Par Value of Shares
The shares issued to specific targets are domestically listed RMB ordinary shares (A shares), with a par value of 1.00 RMB per share.
(II) Issuance Method and Timing
The issuance will be conducted through a private placement to specific targets. The Company will choose an appropriate time to issue shares to specific targets within the prescribed validity period after obtaining approval from the Shenzhen Stock Exchange and the registration consent from the CSRC.
(III) Issuance Targets and Subscription Method
The target of this issuance is Rulian Investment, which will subscribe for the shares in cash.
(IV) Pricing Benchmark Date, Pricing Principles, and Issuance Price
The pricing benchmark date for this issuance is the first day of the issuance period. After the issuance is registered by the CSRC, the issuance period will be determined by the Board of Directors or its authorized persons, as authorized by the general meeting of shareholders, based on market conditions and the principle of protecting the interests of small and medium-sized shareholders.
The issuance price shall not be lower than 80% of the average trading price of the Company's shares for the 20 trading days prior to the pricing benchmark date (Average trading price = Total trading volume for the 20 trading days prior to the pricing benchmark date / Total trading volume for the 20 trading days prior to the pricing benchmark date). If the Company experiences ex-rights or ex-dividend events such as dividend distribution, bonus shares, or capitalization of capital reserves between the pricing benchmark date and the issuance date, the issuance price will be adjusted accordingly. The adjustment formulas are as follows:
Dividend distribution/cash dividends: P1 = P0 - D
Bonus shares or capitalization of capital reserves: P1 = P0 / (1 + N)
Both events occurring simultaneously: P1 = (P0 - D) / (1 + N)